8 April 2024 ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by NCI for iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer
4 April 2024 ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation
26 February 2024 ORYZON reports financial results and corporate update for quarter ended December 31, 2023
19 January 2024 ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
5 January 2024 ORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline Personality Disorder (BPD)